Systemic failures in pharmaceutical regulation: 1M+ eye drops recalled amid FDA oversight gaps and corporate negligence

Indigenous knowledge systems treat pharmaceutical safety as part of a broader ecological and spiritual framework, where contamination is not just a technical failure but a violation of relational ethics between humans, land, and non-human kin. The Navajo concept of *Hózhǫ́* (harmony) extends to medicinal purity, where sterile production is inseparable from respect for the land and community well-being. These systems often lack the institutional power to influence Western regulatory bodies, leaving their holistic approaches sidelined in favor of profit-driven compliance models.

The FDA’s current inspection gaps trace back to the 1980s deregulatory wave under Reagan, which shifted the agency’s role from proactive oversight to reactive enforcement, creating a culture of corporate self-regulation. The 2007 FDA Amendments Act, while expanding authority, was gutted by industry lobbying, leaving the agency chronically underfunded—today, it inspects foreign manufacturing facilities at a rate of once every 13 years on average. This historical trajectory mirrors other industries where deregulation led to predictable crises, such as the 2008 financial collapse or the Deepwater Horizon disaster.

In Japan, the *yakkyoku* (pharmacy) system integrates rigorous in-house testing with community pharmacist oversight, reducing reliance on centralized regulatory bodies. China’s *zhongyi* (traditional Chinese medicine) sector, while not immune to contamination, often employs multi-layered quality control that includes seasonal harvesting and ecological validation. These models contrast with the FDA’s adversarial approach, where inspections are treated as punitive rather than collaborative. The Western framework’s emphasis on individual liability also diverges from communal accountability systems, where entire villages share responsibility for medicinal safety.

Sterility failures in eye drops are often linked to inadequate environmental controls in manufacturing, particularly in facilities with cost-cutting measures like reduced air filtration or improper sterilization of raw materials. The FDA’s reliance on *in-process* inspections rather than real-time monitoring allows contamination to persist undetected until post-market surveillance catches it. Studies show that facilities with repeated violations share common traits: high production volumes, reliance on third-party suppliers, and a history of prior warnings without meaningful penalties.

Artistic and spiritual traditions often frame contamination as a metaphor for societal decay, where the body’s purity reflects the health of the collective. In Islamic *tibb* (prophetic medicine), the concept of *tayyib* (wholesome) extends beyond physical safety to include ethical sourcing and intention in production. Similarly, in African diasporic traditions like Hoodoo, medicinal contamination is seen as a breach of spiritual contracts, requiring purification rituals to restore balance. These perspectives challenge the Western reductionist view of sterility as a purely technical issue.

Modeling future pharmaceutical safety requires shifting from reactive recalls to predictive systems that integrate blockchain-based supply chain tracking, AI-driven anomaly detection, and community-based reporting networks. Scenario planning suggests that without structural reforms, similar crises will emerge in biologics and gene therapies, where contamination risks are even higher due to complex manufacturing processes. The rise of decentralized medicine (e.g., compounding pharmacies) may also force regulators to adopt more adaptive, localized oversight models.

Low-income communities and people of color are disproportionately affected by pharmaceutical contamination due to under-resourced healthcare systems, limited access to alternative medications, and a history of medical experimentation that erodes trust in regulatory bodies. Rural populations, often served by the recalled products, lack the political capital to demand systemic changes, while Indigenous and immigrant communities face additional barriers in navigating FDA complaint processes. The FDA’s failure to center these voices in its oversight reflects a broader pattern of institutional neglect toward marginalized groups.